News

h_da joins ASPIRE
28. March 2023
We proudly announce that the ASPIRE team has a new member: Darmstadt University of Applied Sciences joins the consortium and brings in expertise for AI-based brain image analysis and atlas creation. Together we will establish a platform independent dementia diagnosis support based on arterial spin labeling images.

mTRIAL 3.4. release
21. March 2023
We proudly announce the release of our new mTRIAL version. For the first time it incorporates a webbased comprehensive DICOM image viewer for platform independent and real time access of clinical trial data. Central read workflow planning and execution has been upgraded for even more reliable and efficient review of radiological data. mTRIAL 3.4. – ready to support your next image based clinical trial.

Welcome Yaqueen!
14. March 2023
We are very happy to welcome our new team member Yaqeen Ali. He joined mediri for his PhD as Marie Skłodowska-Curie-Fellow. He has completed his master’s degree in Computer Science at Comsats University Islamabad, Pakistan. Together with 9 other Phd students all over Europe he will work in the BosomShield Project aiming at a CAD system for breast cancer relapse prediction. Yaqeen will develop a prototype for a secure remote solution with web access for patient-individual multi-modal image analysis using cloud computing and federated learning.
Looking very much forward to this exciting project with Universitat Rovira i Virgili, KTH Royal Institute of Technology Radboudumc, Institut d’Investigació Sanitària Pere Virgili – IISPV, Nalecz Institute of Biocybernetics and Biomedical Engineering Polish Academy of Sciences, University of Udine, UBFC – Université Bourgogne-Franche-Comté, Univerza v Mariboru and nVision Systems.

Digital Innovator Award 2023
13. March 2023
We proudly announce that mediri has been awarded as Digital Innovator 2023 in the category „medical technology and pharmaceuticals“ by CHIP. In times of digitization, CHIP and data analysis specialist Globis Consulting have studied the innovative power of German companies and institutes in digitization. CHIP is known as one oft the top recommendation brands.
See the full ranking here.

aerzteblatt article
07. February 2023
If you have two minutes, take a look at this aerzteblatt article about artificial intelligence that is mentioning mediri and the DeepRAY project.
ASPIRE meeting
31. January 2023
Working visit at Amsterdam UMC: The partners in the ASPIRE project spent two days at Amsterdam UMC to pave the way for the final year. ASPIRE will ease the access to non-invasiv imaging biomarkers in dementia and help to get ASL into the clinics.

mTRIAL Freesurfer
30. January 2023
The easiest way to use FreeSurfer for brain volume measurements? Upload your FLAIR images to mTRIAL and enjoy the magic.
Interested? Don’t hesitate to contact us.
mTRIAL LST Report
17. January 2023
You want the brain MRIs of your MS patients to be evaluated by the SPM Lesion Segmentation Tool but without installing and adapting any software packages? Or do you need consistent evaluations across multiple centres of a clinical trial? mTRIAL offers Lesion analysis of FLAIR images based on the SPM LST algorithm and produces clear reports. You only need to upload your image data to the mTRIAL platform, pseudonymization is performed on the fly, evaluation and reporting can be done within minutes.
Interested? Don’t hesitate to contact us.
Merry Christmas
20. December 2022
Many thanks to all colleagues, partners and friends for a year full of fruitful discussions, exciting projects and fresh ideas. Enjoy the holidays with your loved ones and have a good start into the new year.

Advancements of ASL
13. December 2022
30 years after the first successful Arterial Spin Labeling (ASL) MR image acquisition to measure cerebral blood flow in rat brain, the early detection of Alzheimer’s using ASL gains enormous importance with the recent publication of the study results for Lecanemab. Now that there is hope for efficient therapies in dementia diseases, it is a good time to review the steps that have been gone since then. Many initiatives aiming at reliable and comparable quantification of brain perfusion measurements are paving the way for broad usage of ASL in clinical studies focusing on Alzheimer‘s and other dementia diseases.
